Bright Minds Biosciences’ (DRUG) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Bright Minds Biosciences (NASDAQ:DRUG) in a research report released on Wednesday morning,Benzinga reports. They currently have a $85.00 price target on the stock. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.30) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.79) EPS, FY2026 earnings at ($5.63) EPS, FY2027 earnings at ($5.72) EPS, FY2028 earnings at ($5.80) EPS and FY2029 earnings at ($1.70) EPS.

Several other analysts also recently issued reports on the company. Robert W. Baird initiated coverage on Bright Minds Biosciences in a report on Monday, November 25th. They issued an “outperform” rating and a $75.00 price target for the company. Cantor Fitzgerald initiated coverage on Bright Minds Biosciences in a report on Friday, January 10th. They issued an “overweight” rating for the company. Baird R W upgraded Bright Minds Biosciences to a “strong-buy” rating in a report on Monday, November 25th. Finally, Piper Sandler initiated coverage on Bright Minds Biosciences in a report on Thursday, January 23rd. They issued an “overweight” rating and a $93.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $84.33.

Bright Minds Biosciences Stock Down 0.4 %

Shares of NASDAQ DRUG opened at $35.99 on Wednesday. Bright Minds Biosciences has a 52-week low of $0.93 and a 52-week high of $79.02. The firm has a fifty day moving average of $37.98 and a 200-day moving average of $26.48. The stock has a market capitalization of $253.37 million, a PE ratio of -211.69 and a beta of -6.71.

Bright Minds Biosciences (NASDAQ:DRUG) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.24. Equities research analysts expect that Bright Minds Biosciences will post -1.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Bright Minds Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DRUG. Janus Henderson Group PLC purchased a new position in Bright Minds Biosciences in the 4th quarter valued at about $18,392,000. RA Capital Management L.P. purchased a new position in Bright Minds Biosciences in the 4th quarter valued at about $16,599,000. Vivo Capital LLC purchased a new position in Bright Minds Biosciences in the 4th quarter valued at about $9,062,000. Point72 Asset Management L.P. purchased a new position in Bright Minds Biosciences in the 4th quarter valued at about $4,870,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Bright Minds Biosciences in the 4th quarter valued at about $4,773,000. 40.52% of the stock is owned by hedge funds and other institutional investors.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.